Back to search
FDAFDA · Food and drugs·Recall number D-0602-2024

Cardura XL (doxazosin) extended release tablets 4mg, 30-count bottles, Rx Only, Made in Singapore, Distributed by Roerig Division of Pfizer Inc, NY, NY 10017 NDC 0049-2040-10

Published July 24, 2024 · Recall initiated: April 30, 2024

Summary

FDA records drug Class II recall D-0602-2024, published July 24, 2024 and initiated April 30, 2024. Recalling firm: Viatris Inc; Status: Completed; Reported quantity: 12,691 bottles; Lot: Lot #: 8147040; Exp. June 2024 Lot #: 8163764; Exp. March 2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Viatris Inc
Distributor
U.S. Nationwide
Lot
Lot #: 8147040; Exp. June 2024 Lot #: 8163764; Exp. March 2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Cardura XL (doxazosin) extended release tablets 4mg, 30-count bottles, Rx Only, Made in Singapore, Distributed by Roerig Division of Pfizer Inc, NY, NY 10017 NDC 0049-2040-10 recalled?

Yes. FDA published recall D-0602-2024 on July 24, 2024. Reported hazard: Failed Impurities/Degradation Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter